Xolair 75 MG/0.5 ML syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSCE6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,689
Award facts
- Contract value 100% obligated
- $23,688.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $23,688.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 75 mg/0.5 mL syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of February 11, 2026, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents one of numerous delivery orders issued to DMS Pharmaceutical Group under its broader pharmaceutical supply relationship with the Defense Logistics Agency.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring pharmaceutical and medical supply needs for Department of Defense healthcare facilities worldwide. The parent contract, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical pharmaceutical supplier for military healthcare operations globally. As a biologic immunosuppressant medication, Xolair supports specialized pharmaceutical requirements within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FSCE6?
SPE2DR26FSCE6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FSCE6 worth?
The government has obligated $23,689 on SPE2DR26FSCE6.
Is contract SPE2DR26FSCE6 an order under another contract?
Yes. SPE2DR26FSCE6 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCE6 competed?
The extent of competition for SPE2DR26FSCE6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award